)
Edge31 Oct 2025
Rolls-Royce: Full Thrust Ahead
From century-old crafted perfection to pandemic shock and reset, Rolls-Royce's story is shaped by heritage, turbulence, and a disciplined climb back.
Nuvation Bio (NUVB) investor relations material
Nuvation Bio Q3 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q3 2025 earnings summary3 Nov, 2025
Executive summary
Achieved first full commercial quarter post-FDA approval of atrozine/IBTROZI in June 2025, with 204 new patient starts and rapid adoption in ROS1-positive NSCLC; regulatory approvals also obtained in Japan and China.
Expanded global reach with ongoing commercialization in China and advanced discussions for European partnerships.
Significant pipeline progress with initiation of pivotal phase III study for saflosotinib/safusidenib in high-grade IDH1-mutant glioma and continued development of NUV1511.
Net loss for Q3 was $55.8 million, reflecting increased R&D and SG&A investments.
Financial highlights
Q3 2025 total revenue was $13.1 million, including $7.7 million in U.S. atrozine/IBTROZI sales and $5.4 million in collaboration/license revenue.
Gross profit for Q3 2025 was $9.8 million; gross margin was approximately 74%.
R&D expenses were $28.8 million; SG&A expenses were $37.4 million, reflecting commercialization investments.
Cash, cash equivalents, and marketable securities totaled $549 million as of September 30, 2025.
Net loss per share was $0.16 for Q3 2025.
Outlook and guidance
Not providing formal net revenue guidance, but annualized net revenue from Q3 patient starts would exceed $55 million if patients remain on therapy for 12 months.
Confident in consensus estimates for 2026 of $115 million in revenue, with significant growth potential as first-line adoption increases.
$25 million milestone payment expected from Japan upon reimbursement price establishment by year-end.
Anticipates taletrectinib listing on China’s National Reimbursement Drug List in 2026.
Update from NUV-1511 Phase 1/2 study expected by year-end 2025.
Atrozine: Strategy for community center uptake?
Saflosotinib: Low-grade glioma strategy post-pivot?
Atrozine: Adjuvant and RNA testing market impact?
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Next Nuvation Bio earnings date
Jefferies London Healthcare Conference 202519 Nov, 2025
Next Nuvation Bio earnings date
Jefferies London Healthcare Conference 202519 Nov, 2025
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Nuvation Bio Inc. is a clinical-stage biopharmaceutical company dedicated to addressing some of the most significant unmet needs in oncology. The company is focused on the development of differentiated and novel therapeutic candidates, aiming to significantly change the practice of oncology through medicines that offer meaningful improvements in quality of life and survival for cancer patients. Nuvation Bio's approach includes a wholly-owned deep pipeline of six differentiated and novel investigational oncology therapeutic candidates targeting critical pathways that cancer cells use for growth. The company is headquartered in New York, New York, and its shares are listed on the NYSE.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage